These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35676813)

  • 1. Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells.
    Wei L; Ma W; Cai H; Peng SP; Tian HB; Wang JF; Gao L; He JP
    Biomed Environ Sci; 2022 May; 35(5):419-436. PubMed ID: 35676813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    Yu J; Gao G; Wei X; Wang Y
    BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
    Ho KH; Chen PH; Chou CM; Shih CM; Lee YT; Cheng CH; Chen KC
    Neurotherapeutics; 2020 Jul; 17(3):1212-1227. PubMed ID: 31916238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
    Stéphanou A; Ballesta A
    Pharmacol Res Perspect; 2019 Feb; 7(1):e00454. PubMed ID: 30705757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.
    Patties I; Kallendrusch S; Böhme L; Kendzia E; Oppermann H; Gaunitz F; Kortmann RD; Glasow A
    J Exp Clin Cancer Res; 2019 Oct; 38(1):420. PubMed ID: 31639020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
    Xu JX; Yang Y; Zhang X; Luan XP
    Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
    Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
    Wang S; Chen C; Li J; Xu X; Chen W; Li F
    J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.